In July 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) convened to vote on seven peptides: BPC-157, TB-500, KPV, MOTS-c, Semax, Epithalon, and DSIP. If you are in the peptide space at all, you probably saw the coverage. Most of it missed the point.
So let me be direct about what this committee actually decides, because the confusion is creating a lot of unnecessary anxiety. And some very misplaced confidence.
What the PCAC actually is
The Pharmacy Compounding Advisory Committee is an FDA advisory body that evaluates substances to determine whether they are appropriate for use in compounded drug preparations. The key word is compounded.
Compounding pharmacies are licensed pharmacies that prepare customized medications for individual patients under a prescriber's order. They operate under a specific legal framework (503A and 503B of the Federal Food, Drug, and Cosmetic Act). When the PCAC evaluates a substance, the narrow question it is answering is: can a licensed compounding pharmacy prepare this compound for a patient with a valid prescription?
That is it. That is the whole question.
The PCAC does not regulate research use. It does not govern what adults do with substances outside the prescription pathway. It does not determine the legality of the compounds themselves for research purposes. What it decides is whether they can be legally dispensed by a licensed pharmacy as a compounded prescription drug.
If a compound gets placed on the "do not compound" list, it means a licensed pharmacy cannot prepare it for a patient walking in with a script. It does not mean the compound has been banned, declared dangerous, or made illegal for research use.
Peptexa editorial noteThe seven peptides under review
Here is a plain-language summary of the compounds the committee reviewed and why each one matters:
- BPC-157: Body Protection Compound, gastric-derived peptide with extensive rodent healing data. One of the most-used research peptides in existence.
- TB-500: Synthetic fragment of Thymosin Beta-4. Systemic repair and inflammation modulation. Widely used in athletic recovery contexts and veterinary settings.
- KPV: Tripeptide fragment of alpha-MSH. Primarily studied for gut inflammation and wound healing. Less mainstream but active research area.
- MOTS-c: Mitochondria-derived peptide involved in metabolic regulation and exercise response. Early but compelling research.
- Semax: Synthetic ACTH fragment. Primarily studied for neuroprotection and cognitive function. Popular in Eastern European medical practice.
- Epithalon: Synthetic tetrapeptide. Studied for anti-aging effects via telomerase activation and pineal gland function. Limited but interesting human data.
- DSIP: Delta Sleep-Inducing Peptide. Studied for sleep regulation and stress response. Smaller following than the others on this list.
Why the compounding pathway matters anyway
Even though the PCAC's authority is narrow, the practical stakes are real. For many people who have been using these compounds through clinician-supervised pathways, peptide clinics, functional medicine practices, longevity doctors, the compounding pharmacy was the sourcing mechanism. A prescription from a physician, filled by a licensed 503A pharmacy. That is a legitimate, quality-controlled supply chain with accountability built in.
If these compounds are removed from the compounding-permitted list, those patients lose access to that pathway. They do not disappear. They move to other sourcing options. Which in most cases means less oversight, not more. That outcome is worse for the people the regulation is ostensibly trying to protect.
That is the argument that the peptide and integrative medicine community has been making, and it is a reasonable one.
What this review does not change
Research use, self-directed use, and the broader gray market for these compounds operate outside the compounding framework entirely. The PCAC vote does not touch that world. Whatever the committee decided [Update: The committee recommended six of the seven for inclusion. see the full analysis →], millions of people who have been using these compounds will continue to have access to them through research chemical suppliers.
What changes, if adverse determinations are issued, is whether the safest, most quality-controlled pathway (licensed pharmacy, physician oversight) remains available. The irony is that restricting the legitimate pathway tends to push volume toward the less regulated one, not eliminate use.
Get the free Peptexa Top-5 guide
Five of the most-researched compounds, mechanism, evidence level, and current FDA status explained plainly.
Get the Free Guide →Questions I get asked
FDA's own review teams recommended against all seven. The committee overruled the agency's scientific staff on six of them. These are non-binding recommendations; the FDA has not issued a final ruling, and nothing about the current legal status of any of these substances has changed.
Read the full compound-by-compound analysis →
The distinction is not just regulatory classification. FDA's review noted that multiple salts and derivatives. including different active moieties. are sold commercially under the same common name, and that a certificate of analysis it located in the public domain carried no impurity limits, no aggregation data, and no bioburden or endotoxin testing. The label reflects a regulatory pathway. What's in the vial depends on who made it.
Stay ahead of the regulatory curve
The Peptexa newsletter covers FDA updates, new research, and what it means for the peptide space. No fluff.